TScan Therapeutics, Inc.
TCRX· Nasdaq
TCRXTScan Therapeutics, Inc.
Filed May 10, 2023 · 10-Q · 40 days after period end · 0000950170-23-020087
| Metric | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|
| Revenue | $6.80M | $3.02M | $2.03M |
| Net Income | -$22.56M | -$16.16M | -$7.91M |
| EPS Diluted | -$0.93 | -$0.67 | -$6.49 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end
